{"entity":{"id":"wuxi-biologics","kind":"company","name":"WuXi Biologics","aka":["药明生物","WuXi XDC"],"tldr":"WuXi Biologics develops and manufactures antibodies for hundreds of clients worldwide, and its WuXi XDC unit is the largest contract maker of antibody-drug conjugates.","summary":"Discovery, cell-line development and GMP manufacture of monoclonal and bispecific antibodies; WuXi XDC (listed separately in Hong Kong, 2268.HK) runs integrated ADC conjugation for a large share of clinical-stage ADCs from both Chinese and Western sponsors. Named in the US BIOSECURE Act; sold its Irish vaccine plant to Merck in 2025. The company behind much of the antibody supply for China's PD-1 and ADC boom.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.wuxibiologics.com/"}],"tags":["china"],"related":[],"cancers":[],"sections":["adcs","immunotherapy"],"technologies":["adc","monoclonal-antibody","bispecific-antibody"],"targets":[],"drugs":[],"companies":["wuxi-apptec"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["li-ge"],"bottlenecks":["b-regulatory-fragmentation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Wuxi / Shanghai","country":"CN","companyType":"cro-services","website":"https://www.wuxibiologics.com/","ticker":"2269.HK","founded":2010,"investors":[],"funding":[]},"route":"/companies/wuxi-biologics/","neighbours":{"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"downstream-purification-chromatography","kind":"technology","name":"Downstream purification (Protein A capture, viral clearance, polishing)","route":"/technologies/downstream-purification-chromatography/"},{"id":"pharmaceutical-gmp-inspections","kind":"technology","name":"GMP, inspections, Form 483s and warning letters","route":"/technologies/pharmaceutical-gmp-inspections/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"company":[{"id":"wuxi-apptec","kind":"company","name":"WuXi AppTec","route":"/companies/wuxi-apptec/"}],"person":[{"id":"li-ge","kind":"person","name":"Ge Li","route":"/people/li-ge/"}],"bottleneck":[{"id":"b-regulatory-fragmentation","kind":"bottleneck","name":"Regulatory divergence between regions","route":"/bottlenecks/b-regulatory-fragmentation/"}]}}